trending Market Intelligence /marketintelligence/en/news-insights/trending/gqhxvloj-wb3de7aipmmia2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Lannett receives FDA's supplemental approval for morphine solution

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Lannett receives FDA's supplemental approval for morphine solution

Lannett Co. Inc. received approval from the U.S. FDA for the supplemental new drug application of its morphine sulfate oral solution CII.

The solution is an opioid agonist indicated for the management of acute and chronic pain in opioid-tolerant patients severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Lannett CEO Arthur Bedrosian stated that the company expects to launch the solution soon.

Total U.S. sales for the 12 months ended October for morphine sulfate oral solution, at average wholesale price, were about $22 million, according to IMS Health data.